Striving to defeat cancer and other illnesses, Fred Hutch researchers regularly conduct innovative infectious disease research and global clinical trials. These life-saving efforts require meticulous data management and adherence to international compliance standards.
Over the past 25 years SCHARP has conducted more than 250 HIV prevention and vaccine studies in domestic and international sites. SCHARP and its partner SDMCs are currently managing nearly 90 phase I – III clinical trials, with more than 40 actively enrolling or following participants. The studies are being conducted at over 150 clinical sites in more than 25 countries around the world.
Established in 1992 to support global HIV prevention research at Fred Hutch, we have since expanded to support additional therapeutic areas including oncology and other infectious diseases. SCHARP operates according to all national and international regulatory standards. Our team with over 150 clinical trials specialists are skilled in biostatistics, programming, IT data systems, quality assurance, project management and clinical and lab data management collected from multiple sources worldwide.
Our Statistical and Data Management Services
SCHARP supports clinical researchers and administrators with high quality clinical and laboratory data management and statistical services.
Major SCHARP Research Projects
SCHARP provides statistical support and data management services to researchers worldwide in the fight against HIV/AIDS, cancer, and other infectious diseases.
Funded by the National Institutes of Health, HVTN oversees worldwide clinical trials to test vaccines against HIV/AIDS. The network designs and conducts all phases of clinical trials, from evaluating experimental vaccines for safety and immunogenicity to testing vaccine efficacy.
Founded in 2000, HPTN researches integrated strategies for HIV prevention, including antiretroviral drugs and behavioral interventions. The global network evaluates new HIV prevention interventions and strategies in populations and geographical regions that bear a disproportionate burden of infection.
Established in 2006, MTN conducts studies aimed at developing topical or oral antiviral medications to reduce transmission of HIV/AIDS. The network includes more than 25 clinical research sites in seven countries worldwide.
VISC is a Bill & Melinda Gates Foundation-funded program that provides statistics support for the Foundation’s HIV vaccine development initiative, Collaboration for AIDS Vaccine Discovery (CAVD). VISC partners with SCHARP for management of lab data and other critical operational support.
Nearly a quarter of the world’s cancers are caused by infectious diseases that are preventable or treatable. We address these cancers by focusing on the support of research, clinical care and training of cancer specialists, scientists and support staff in Uganda and other countries. Our mission is to reduce the burden of cancers around the world through improved diagnosis, better prevention strategies and optimized treatment plans.